ACRO originated from a group of scholars at the University of Taiwan with the founder Richard Chu, looking for the materials for disease treatment and health care from the traditional Chinese medicine and natural herbal medicine. First, to find the target from the rule of thumb in Chinese medicine usage and then validate and develop by science methods. The preferred material is China treasure, “Cordyceps”.
After 12 years of research and development, more than 2,000 people/years investment, ACRO has been transferred from agricultural cultivation to biotechnology research, including genetic engineering and molecular engineering. ACRO referred from the ancient herb usage, integrated advanced technologies including microbial species management and compound extraction with numerous experiments for new applications. The scientific co-operated study results are extraordinary by various research institutions cross China, Taiwan, Japan and the United States.
The research issues are expanded years by years. After Cordyceps, ACRO developed the Taiwanese endemic species of fungus –〝Antrodia Cinnamomea〞as a core material for medical usage. ACRO also discovered in a rare natural material -〝Marine elements〞which in east of Taiwan, especially from the deep Pacific Ocean upward flow. Third, the precious micro protein -〝Metallothionein〞manufacturing including molecular engineering, fermentation and purification was established by ACRO.
For the decade success, core technologies leaded core materials. In Taiwan, and Japan, and China, ACRO has provided several important products in health markets and Bio-industry development by technical support. In 2016, ACRO reached an important milestone, composed RD team, market team, and management team to established ACRO BIOMEDICAL CO., LTD in America, listed on OTC Market.